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Abstract - In search for a delivery approach for thymidine monophosphate (TMP) in 
bacterial cells, we have synthesized a series of conjugates of TMP with biotin having an 
oxymethyleneoxy ester, a carboxy ester and different carboxamide linkers between the 
carboxyl group of biotin and the 3’-OH group of TMP. The synthetic strategy starts from 
5’-O-(dibenzylphosphate)-thymidine having the linkers already connected at the 3’-
position. Likewise, kanamycin A was linked at the 3’-position of TMP using a carbamoyl 
or thioethyl carbamoyl group. None of the conjugates were able to sustain growth of a 
 ∆thyA, ∆phoA E. coli strain. 
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1. INTRODUCTION 
 
Creating artificial genetic systems capable of supporting Darwinian evolution is of prominent 
importance to synthetic biology, not only to achieve expansion of the genetic alphabet but 
specially for the genetic reprogramming of engineered microorganisms.[1] The in vivo synthesis of 
xeno nucleic acids (XNAs), however, is thought to entail high intracellular consumption of 
unnatural nucleotide building blocks, which will thus need to be provided to the host cell, as most 
modified nucleosides are poorly phosphorylated by natural kinases. Nucleotides however suffer 
from low cell-penetrating ability and generally undergo fast enzymatic dephosphorylation before 
being taken up. Their bacterial uptake is further complicated by the complex multi-layered wall 
structure, which makes prokaryotic cells commonly more difficult to penetrate compared to 
eukaryotic membranes.  
Thus far, efforts have focused on overexpression of endogenous kinases to broad enzyme-
substrate specificity,[2] and more recently, on the transfection of E. coli with a plasmid encoding 
an algal nucleotide triphosphate transporter to enhance triphosphates uptake.[3] Despite the 
ground-breaking value of this last approach, which resulted in the first in vivo replication of an 
unnatural DNA base pair, its universal applicability to all unnatural bases and types of backbone 
modifications is yet unpredictable. 
In a previous paper, we discussed our interest in the development of a delivery tool for active 
uptake of nucleotides in bacterial cells based on a nutritional selection approach.[4] The 
general concept consists in linking the information system to an extracellular nutrient 
essential for the cell, thus taking advantage of natural transport pathways. A biocleavable 
covalent bond is designed to maintain the conjugate intact during cellular uptake, but allow 
facile release of the nucleotide intracellularly. Building on previous studies, thymidine 
monophosphate is selected as archetypal nucleotide system.[5] The relevant TMP conjugate is 
supplied within the nutrient medium to a bacterial strain deleted for the ThyA gene encoding 
for thymidilate synthase, which is known to unconditionally require thymine or thymidine for 
growth.  
Because of the novelty of our delivery approach, we decided to investigate a large diversity 
of biological carriers, such as peptides and vitamins. We describe here the synthesis of 
biotin-TMP conjugates. The appeal of this choice is due to the fact that biotin-negative 
mutants are also well-established auxotrophs and can provide additional functional 
evidence.[6, 7] 
Expanding upon this idea, we also wish to prove the same concept using an inverse selection 
method. As in most cases, antimicrobial compounds penetrate prokaryotic cell membranes 
effectively through relatively non-specific transport systems, we describe here also the 
synthesis of conjugates of nucleotides with Kanamycin A. Aminoglycosides (AGs) are 
clinically relevant drugs, which show broad-spectrum antibacterial activity against both 
gram-negative and gram-positive species, binding irreversibly to the prokaryotic ribosome 
and mainly interfering with peptide elongation at the 30S subunit.[8, 9] Although the detailed 
mechanism by which AGs penetrate into the bacterial cytoplasm remains unclear, their 
uptake is know to be a multistep energy requiring process that can be accumulated against a 
concentration gradient.[10, 11] In this case, the observation of toxicity would ensure uptake and 
processing of the nucleotide by the cell. 
 
2. RESULTS AND DISCUSSION 
 
Our retrosynthetic analysis for the planned carrier-TMP target compounds is shown in Figure 1. 
It becomes apparent that those conjugates can be accessed by either linking the carrier unit at the 
3'-position of thymidine followed by 5’-O-phosphorylation (Route 1), or viceversa (Route 2).  
 
 
 
 
Figure 1. Retrosynthetic analysis of carrier-TMP conjugates. 
 
Initially, we decided to follow Route 1 (Figure 1) by applying the same optimized conditions 
employed for the synthesis of peptide-TMP conjugates connected though an oxymethyleneoxy 
ester bond.[4] Coupling of biotin at the 3’-position of methylene thiomethyl thymidine derivative 
1, obtained in turn from thymidine in 60% yield over two steps, and subsequent removal of the 
5’-silyl group, proceeded efficiently giving compound 3 in good yield; however, further 
phosphorylation caused oxidation at the sulfur atom of biotin, during the conversion step from PIII 
to PV, giving undesired sulfoxide and sulfone by-products (Scheme 1A). Various mild conditions 
were attempted to attain selective phosphorus oxidation, including dilute solutions of I2,[12] m-
chloroperbenzoic acid (MCPBA)[13] and (1S)-(+)-(10-camphorsulfonyl) oxaziridine[14] but none 
gave the desired product. Switching to the alternative disconnection, 5’-O-(dibenzylphosphate)-
thymidine 5 was therefore prepared in four steps and subsequently subjected to coupling with 
biotin, leading to the formation of the desired compound 7 after deprotection (Scheme 1B). 
However, we found that the Pummerer rearrangement of compound 5 to 6 was less effective than 
in the previous route, probably due to side reaction of the electrophilic sulfur intermediate at the 
nucleophilic phosphate center. 
During the last step, formation of side products resulting from conjugate decomposition were 
observed, pointing at instability of this type of linker under hydrogenation conditions.  
 
 
Scheme 1. Synthesis of 3'-O-methyleneacyloxy-TMP biotin conjugate 7. Reagents and conditions. (a) 
(i) SO2Cl2, DCM, 0 °C to rt, 2 h, (ii) Biotin, DBU, DCM, rt, 24 h; (b) Et3N.3HF, THF, rt, 72 h; (c) 
DMSO, Ac2O, AcOH, rt, 48 h; (d) 10% Pd/C (Degussa), Et3N, MeOH, rt, 16 h. 
 
Different biotin-TMP analogues with carboxyamido-type linkers 10 (Scheme 2) and 13 
(Scheme 2) were prepared adopting previously optimized coupling and debenzylation 
procedures, which required access respectively to 3’-O-amino thymidylate 8 (obtained in 4 
steps from thymidine) and 3’-O-aminoxymethyl thymidylate 11 (obtained in 6 steps from 
thymidine).[4] In general good to excellent isolated yields of products were obtained and 
linker cleavage did not occur in the last step. 
 
 
 
Scheme 2. Synthesis of 3'-O-(carboxamide)-TMP biotin conjugate 10. Reagents and conditions. (a) Biotin, 
DCC, DMAP, DCM/DMF, rt, 24 h; (b) 10% Pd/C (Degussa), MeOH, rt, 24 h. 
 
 
 
 
Scheme 3. Synthesis of 3'-O-methyloxycarboxamide-TMP biotin conjugate 6. Reagents and conditions. (a) 
Biotin, DCC, DMAP, DCM/DMF, rt, 24 h; (b) 10% Pd/C (Degussa), Et3N, MeOH, rt, 24 h. 
 
The 3’-caboxy ester conjugate 15 was also prepared similarly, starting from 5 in 65% overall 
yield over two steps (Scheme 4). 
 
 
 
Scheme 4. Synthesis of 3'-ester-TMP biotin conjugate 15. Reagents and conditions. (a) Biotin, DCC, 
DMAP, DCM/DMF, rt, 24 h; (b) 10% Pd/C (Degussa), MeOH, rt, 24 h. 
 
As Route 2 (Figure 1) proved to be the most profitable for generating new biotin conjugates, we 
chose a similar strategy to connect TMP to kanamycin A by means of a 3’-carbamoyl linker, 
which gave access to conjugates 22 and 24 (Figure 2), and also led to a structural reassignment of 
the aminoglycosidic unit.  
 
 
Figure 2. Structures of kanamycin A-TMP conjugates 22 and 24 and key HMBC correlations used for 
structure determination. Plain arrows ( ) indicate HMBC correlations with the carbamate (OCONH) 
linker (cf. Figure 3A/3B) whilst dotted arrows ( ) show HMBC correlation used for other peak 
assignments. 
 
As cationic amino functionalities of aminoglycosides are considered to be a crucial structural 
requirement for enhanced uptake,[15] we sought to retain all four amino groups of rings I-III in 
kanamycin A. To construct the relevant conjugates efficiently, we exploited the differences in 
chemical reactivity between the primary hydroxy and amino functionalities present in kanamycin 
A. We started by replacing the primary hydroxyl group at the 6''-position of 16 with a 
thioethanolamino group, which would serve for the formation of the desired carbamoyl linkage 
with TMP. The synthesis of compound 19 has been reported by Arya et. al.,[16] however we 
adopted here a shorter synthetic route by modifying a more recent procedure by Tor et. al.[17] 
(Scheme 5). To begin the synthesis, we first needed to selectively protect all four amino groups of 
kanamycin A. Among the several protecting strategies described in the literature, we opted for the 
classical Boc protection, which gave compound 17 in excellent yield. Considering the good 
leaving group properties of triisopropylbenzenesulfonyl chloride (TIBS-Cl), compound 17 was 
selectively sulphonylated at the 6''-primary hydroxyl group to its corresponding sulfonate 18, 
which upon further treatment with 2-aminoethane thiol hydrochloride in the presence of cesium 
carbonate, gave compound 19.  
 
 
 
Scheme 5. Synthesis of kanamycin A cysteamine 19. Reagents and conditions. (a) Boc2O, Et3N, 
DMF/H2O, 50 0C, 6 h; (b) TIBSCl, pyridine, rt, 16 h; (c) HCl.NH2CH2CH2SH, Cs2CO3, DMF, 25 0C, 16 
h.  
 
The introduction of a carbamate linker at the 3’–position of nucleosides is possible starting from 
commercially available isocyanates such as phenyl isocyanates,[18] however this approach appears 
unsuitable for macromolecules containing unprotected polyhydroxyl and polyamino 
functionalities. Another commonly applied method to generate carbamates is the activation of the 
3'-OH group with CDI,[19] but we felt that the strictly anhydrous conditions required by this 
protocol would not be compatible with the poor solubility of most aminoglycosides. A solution 
was found by choosing as activating/leaving group 4-nitrophenyl carbonate,[20] which is 
electrophilic enough to react with amino functionalities, whilst still reasonably stable in aqueous 
media. Compound 20 was prepared in a series of straightforward steps, involving phosphorylation 
at the 5'-position of thymidine after selective protection-deprotection at the 3'- and 5'-position 
with a MMTr and benzoyl group respectively and final 3'-OH activation with 4-nitro phenyl 
chloroformate in a controlled way in the presence of pyridine/DCM. 
With both coupling units now available, we proceeded to react 3’-O-(4-nitrophenylcarbonate)-
TMP 20 with N-Boc kanamycin A cysteamine 19 (Scheme 6A).  
 
 
 
Scheme 6. Synthesis of 3'-carbamoyl kanamycin A-TMP conjugates 22 and 24. Reagents and conditions. 
(a) Et3N, 1,4-dioxane/water, 0 0C to rt, 18 h; (b) 20% Pd(OH)2/C, H2, EtOH/H2O (8:2), rt, 24 h; (c) TFA, 
thioanisole, H2O, rt, 5 h. 
  
Table 1. Reaction circumstances for the synthesis of compounds 21 and 23 from 20. 
Entry Solvent Temp Time (h) Yield of 21a (%) Yield of 23 a (%) 
1 DCM : DMF (1:1) rt 60 48 - 
2 DMF rt 48 55 42 
3 Dioxane : H2O (3:1) 0 °C to rt 16 90 82 
a  Isolated yield 
 
An initial attempt to synthesize 21 using previously optimized conditions in the presence of 
triethylamine as base and DCM/DMF (1:1) as solvent, afforded the desired conjugate in poor 
yield. Replacement of the solvent system with a mixture of 1,4-dioxane/water (3:1), surprisingly 
resulted in an improved yield (90%) (Table 1). Removal of the dibenzyl phosphate protection of 
21 was achieved by catalytic hydrogenolysis using an excess of 20% Pd(OH)2/C to avoid 
potential catalyst poisoning due to the sulfide moiety. Without further purification, the N-Boc 
protected intermediate 21 was converted to compound 22 upon treatment with aqueous TFA, in 
good yield and high purity after preparative RP-HPLC purification. 
 
As the convergent coupling of complex fragments is important to rapidly generate a variety of 
conjugates, we decided to further explore the versatility of this reaction process. Since a single 
aminomethyl group is present in kanamycin A, the regioselective formation of a mono-carbamate 
linker seemed feasible without prior protection of the other amino groups. The 6'-amino group of 
kanamycin A is known to be the most reactive following the series 6'-NH2 > 1-NH2 > 3-NH2 > 
3''-NH2).[21, 22] When we reacted directly compound 20 with kanamycin A 16 utilising the general 
protocol for carbamate formation (Scheme 6B), intermediate 23 was obtained in good yield. 
Subsequent hydrogenolysis in the presence of 20% Pd(OH)2/C and preparative RP-HPLC 
purification yielded compound 24 in good yield and high purity. 
 
Although the reactivity order of the various hydroxyl and amino groups of kanamycin A is well 
documented, we thought necessary to confirm the structures of the final analogues. The peak 
assignment for almost all proton and carbon signals of kanamycin A-TMP conjugates 22 and 24 
was unambiguously determined (Table 2, supporting information), as well as the alignment of the 
carbamoyl linkage between the 9'' and 6' positions (Figure 3A and 3B), by means of two-
dimensional NMR spectroscopy in D2O solution at 25 °C. The presence of a distinctive signal at 
157.5 ppm in the carbonyl region of the carbon NMR spectrum, proton integration ratio along 
with HRMS mass spectrometry confirmed the formation of a single carbamate linkage at the 
expected positions. While performing the 1H and 31P NMR spectroscopic analysis of compound 
22 (Figure 3C and 3D), the appearance of a minor conformation was observed at low temperature 
(5 °C), which disappeared when the temperature was raised (50 °C), indicating the presence of a 
single conformer. This phenomenon may arise due to the formation of rotamers, as the inherent 
flexibility around glycosidic bonds of kanamycin A-TMP conjugates allows them to easily adopt 
an array of conformations. [23] 
 
 
 
 
Figure 3. A) Key HMBC correlation for compound 22; B) key HMBC correlation NMR spectrum of 
compound 24; C) and D) temperature-dependent NMR (1H and 31P) study of compound 22. All NMR 
spectra were recorded in D2O. 
 
 
 
 
 
 
 
 
 
 
 
 
 In order to test the bacterial uptake of all synthetized biotin and kanamycin Α conjugates as a 
source of TMP, an E. coli W2666 thyA(-) strain [spontaneous strepto R mutant of CBO129 (F- 
W1485 leu thyA dcoB or C supE)] was employed. Its genotype is E. coli W2666 ΔthyA ΔphoA. 
This strain is deleted for thyA and phoA genes, which respectively encode for thymidylate 
synthase and alkaline phosphatase, in order to block all pathways that could lead to the formation 
or degradation of TMP inside the bacterial cells. All compounds were preventively submitted to 
LC/MS analysis to exclude potential sample contamination, but no traces of thymine could be 
observed below detection limit. LB medium and LB agar were sterilized by autoclaving (120 °C, 
30 min). Thymine (positive control), TMP (negative control) and all compounds were dissolved 
in MilliQ water and sterilized through a 0.2μm sterile syringe filter (VWR). A single colony of 
the mutant strain was grown overnight at 37 °C in LB medium (3 mL). Cells were then harvested 
by centrifugation, washed and resuspended in fresh LB medium. The bacterial cells were then 
diluted 1:1000 in fresh LB medium before streaking on LB agar plates containing 20μg/mL of 
each compound and grown overnight at 37 °C. Unfortunately, no colony formation 
(compounds 7, 10, 13, 15) or toxicity (compounds 22, 24) were observed.  
 
3. CONCLUSION 
 
In summary, we have accomplished the synthesis of a variety of biotin- and kanamycin A-TMP 
conjugates in a straightforward manner starting from previously optimized 3’-modified TMP 
intermediates and featuring in turn an oxymethyleneoxy ester, a carboxy ester, a carboxamide, a 
carbamoyl and a thioethyl carbamoyl group. On the basis of preliminary biological screening 
none of the conjugates showed functional activity in E.Coli mutants lacking thymine. However, 
this might be due to several factors, for instance high concentrations needed for substantial 
growth, which are currently under further study. As additional evidence, biotin-TMP conjugates 
are undergoing biological evaluation using E. coli mutants lacking biotin.  
 
4. EXPERIMENTAL SECTION 
 
4.1. General  
 
For all reactions, analytical grade solvents were used. Kanamycin A. H2SO4 was purchased from 
Sigma-Aldrich (containing kanamycin B as a 5% impurity). Kanamycin A. H2SO4 salt was 
transformed into its free amino form by treatment with Amberlite IRA-400 ion exchange resin. 
All moisture-sensitive reactions were carried out using oven-dried glassware (135 ºC) under a 
nitrogen or argon atmosphere. Reaction temperatures are reported as bath temperatures. Pre-
coated aluminum sheets (254 nm) were used for TLC. Compounds were visualized with UV light 
(λ = 254 nm). Products were purified by flash chromatography on ICN silica gel 63-200, 60 Å. 
All final compounds were purified by preparative RP-HPLC using a gradient of H2O and MeCN, 
both contains either 50 mmol TEAB or 0.1% TFA as eluent buffer as mentioned. 1H, 13C and 31P 
NMR spectra were recorded on 300, 500 or 600 MHz Bruker spectrometers. Final compounds 
were characterized using 2D NMR (H-COSY, HSQC, HMBC, TOCSY, NOESY) techniques. 
The 1H and 13C chemical shifts were referenced to residual solvent signals relative to TMS as 
internal standard wherever applied. Coupling constants J [Hz] were directly taken from the 
spectra. Splitting patterns are designated as s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet) and br (broad). High-resolution mass spectra were acquired on a quadrupole 
orthogonal acceleration time-of-flight mass spectrometer (Synapt G2 HDMS, Waters, Milford, 
MA). Samples were infused at 3 μL/min and spectra were obtained in positive (or negative) 
ionization mode with a resolution of 15000 (FWHM) using leucine enkephalin as lock mass. 
 
4.2. 5’-O-(tert-Butyl diphenyl silane)-3’-O-(biotinmethyloxyester)-thymidine (2)  
 
A 1M solution of SO2Cl2 in CH2Cl2 (2.07 mL, 2.07 mmol) was added to a stirred solution of 1 
(0.935 g, 0.107 mmol) in dry CH2Cl2 (20 mL) at 0 °C. The reaction mixture was allowed to 
warm slowly to room temperature over 2 h, then it was concentrated using a rotary evaporator 
(bath temperature 10-15 °C) under reduced pressure to give a 3’-O-chloromethylthymidine 
derivative as a light yellowish foam, which was used without further purification. 
In a separate round-bottomed flask, biotin (0.634 g, 2.593 mmol) was suspended in dry CH2Cl2 
(20 mL), and DBU (0.38 mL, 2.51 mmol) was then added. After 15 min, the solution was added 
to the crude 3’-O-chloromethylthymidine derivative (redissolved in dry CH2Cl2, 20 mL), and the 
reaction mixture was kept stirring at room temperature for 24 h. The mixture was then diluted 
with CH2Cl2 (100 mL), and 1M aq. acetic acid (4 mL) was added with vigorous stirring. The 
aqueous layer was discarded, and the organic layer was washed with saturated aq. NaHCO3 (2 x 
50 mL) and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The 
crude residue was purified by column chromatography on silica gel (gradient CH2Cl2/MeOH, 
99:1, v/v; 98:2, v/v; 97:3, v/v) to give 2 (0.91 g, 71%) as a colorless foam. 1H NMR (300 MHz, 
CDCl3) δ = 11.9 (s, 1H, NH-Thy), 7.68-7.65 (m, 4H, Ar-H Ph), 7.51 (s, 1H, H-6), 7.46-7.37 (m, 
6H, Ar-H Ph), 6.94 (s, 1H, NH Bio), 6.91 (s, 1H, NH Bio), 6.27 (dd, J = 8.6, 5.2 Hz, 1H, H-1’), 
5.71 (m, 1H, H-g Bio), 4.92 (m, 1H, H-f Bio), 4.59-4.54 (m, 1H, H-3’), 4.38-4.35 (m, 2H, H-5’ 
and H-5’’), 4.12-4.10 (m, 1H, H-4’), 4.03-3.82 (m, 2H, OCH2O), 3.21-3.14 (m, 1H, H-e Bio), 
2.96-2.82 (m, 2H, H-h Bio and H-h’ Bio), 2.74-2.68 (m, 1H, H-2’), 2.49-2.28 (m, 2H, H-a Bio), 
2.14-2.05 (m, 1H, H-2’’), 1.83-1.65 (m, 4H, H-b and H-d Bio), 1.62 (s, 3H, CH3), 1.55-1.40 (m, 
2H, H-c Bio), 1.11 (s, 9H, tBu); 13C NMR (75 MHz, CDCl3) δ = 172.6 (OCO), 165.0 (C-4), 164.3 
(NHCONH), 151.4 (C-2), 135.4 (Ar-C), 135.2 (Ar-C), 134.3 (C-6), 132.6 (Ar-C), 132.2 (Ar-C), 
130.1 (Ar-C), 130.0 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 111.2 (C-5), 88.1 (OCH2O), 85.1 (C-1’), 
84.5 (C-4’), 81.6 (C-3’), 64.0 (C-5’), 62.1 (C-f Bio), 60.3 (C-g Bio), 55.4 (C-e Bio), 40.7 (C-h, h’ 
Bio), 38.9 (C-2’), 33.8 (C-a Bio), 28.0 (C-c Bio), 27.9 (C-d Bio), 26.9 (tBu), 24.5 (C-b Bio), 19.2 
(1C tBu), 12.1 (CH3-Thy); HRMS for C37H48N4O8SSi [M+H]+ calcd.: 737.3035, found: 
737.3045. 
 
4.3. 3’-O-(biotinmethyloxyester)-thymidine (3) 
 
Triethylamine trihydrofluoride (0.76 mL, 4.67 mmol) was added to a stirred solution of 2 (0.86 g, 
1.17 mmol) in THF (20 mL) in a falcon tube at room temperature. The reaction mixture was 
stirred at room temp. for 72 h, and then it was concentrated under reduced pressure. The crude 
residue was purified by column chromatography on silica gel (gradient CH2Cl2/MeOH, 99:1, v/v; 
96:4, v/v; 93:7, v/v) to give 3 (0.49 g, 84%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ = 
11.34 (s, 1H, NH-Thy), 7.68 (s, 1H, H-6), 6.42 (s, 1H, NH Bio), 6.37 (s, 1H, NH Bio), 6.01 (app 
t, J = 7.0 Hz, 1H, H-1’), 5.30 (dd, J = 20.2, 6.6 Hz, 2H, OCH2O), 5.13 (t, J = 5.1 Hz, 1H, 5’-OH), 
4.39-4.36 (m, 1H, H-3’), 4.33-4.28 (m, 1H, H-g Bio), 4.15-4.10 (m, 1H, H-f Bio), 3.93-3.90 (m, 
1H, H-4’), 3.61-3.56 (m, 2H, H-5’ and H-5’’), 3.13-3.06 (m, 1H, H-e Bio), 2.82 (dd, J = 12.4, 5.1 
Hz, 1H, H-h Bio), 2.57 (d, J = 12.4 Hz, 1H, H-h’ Bio), 2.36 (t, J = 7.4 Hz, 1H, and H-a Bio), 
2.27-2.18 (m, 2H, H-2’ and H-2’’), 1.77 (s, 3H, CH3), 1.66-1.45 (m, 4H, H-b and H-d Bio), 1.42-
1.29 (m, 2H, H-c Bio); 13C NMR (75 MHz, DMSO-d6) δ = 172.4 (OCO), 163.6 (C-4), 162.7 
(NHCONH), 150.5 (C-2), 135.9 (C-6), 109.5 (C-5), 87.4 (OCH2O), 84.8 (C-1’), 83.6 (C-4’), 79.4 
(C-3’), 61.1 (C-5’), 61.0 (C-f Bio), 59.2 (C-g Bio), 55.3 (C-e Bio), 40.2 (C-h, h’ Bio, merged with 
DMSO), 36.9 (C-2’), 33.3 (C-a Bio), 28.0 (C-c Bio), 27.9 (C-d Bio), 24.2 (C-b Bio), 12.2 (CH3-
Thy); HRMS for C21H30N4O8S [M-H]- calcd.: 497.1711, found: 497.1715. 
 
4.4. 5’-O-(Dibenzylphosphate)-3’-O-(methylthiomethyl)-thymidine (6) 
 
Acetic anhydride (10.9 mL) and acetic acid (3.5 mL) were added to a stirred solution of 5 (2.40 g, 
4.78 mmol) in DMSO (15.5 mL). The reaction mixture was stirred at room temperature for 30 h, 
and then it was concentrated under reduced pressure. The residue was neutralized with saturated 
aq. NaHCO3 (230 mL), and the mixture was extracted with ethyl acetate (3 x 170 mL). The 
combined organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude residue was purified by column chromatography on silica gel 
(gradient hexane/EtOAc, 2:1, v/v; 1:1, v/v; 1:3, v/v) to give 6 (1.64 g, 61%) as a colorless foam. 
1H NMR (300 MHz, CDCl3) δ = 8.22 (br s, 1H, NH), 7.37-7.35 (m, 11H, H-6 and Ar-H OBn), 
6.26 (dd, J = 8.2, 5.8 Hz, 1H, H-1’), 5.11-5.00 (m, 4H, 2 x OCH2Ph), 4.64-4.51 (m, 2H, OCH2S), 
4.35-4.31 (m, 1H, H-3’), 4.17-4.09 (m, 3H, H-4’, H-5’ and H-5’’), 2.34-2.26 (m, 1H, H-2’), 2.11 
(s, 3H, SCH3), 1.92-1.81 (m, 4H, H-2’’ and CH3-Thy); 13C NMR (75 MHz, CDCl3) δ = 163.4 (C-
4), 150.2 (C-2), 135.6 (d, 3JC,P = 6.1 Hz, 1C of OCH2Ph), 135.3 (C-6), 129.0 (Ar-C), 128.9 (Ar-
C), 128.2 (Ar-C), 111.5 (C-5), 85.0 (C-1’), 82.8 (d, 3JC,P = 8.2 Hz, C-4’), 76.3 (C-3’), 74.1 
(OCH2S), 69.9-69.8 (2 x d, 2JC,P = 3.5 Hz, 2 x OCH2Ph), 67.0 (d, 2JC,P =5.7 Hz , C-5’), 37.5 (C-
2’), 14.0 (SCH3), 12.5 (CH3-Thy); 31P NMR (121 MHz, CDCl3) δ = -0.5; HRMS for 
C26H31N2O8PS [M-H]- calcd.: 561.1466, found: 561.1461. 
 
 
4.5. 5’-O-(Dibenzylphosphate)-3’-O-(biotinmethyloxyester)-thymidine (4) 
 
Following a similar procedure as the one used for the synthesis of 2, compound 4 was obtained 
(41.0 mg, 51%) as a colorless foam, starting from 6 (60.0 mg, 0.107 mmol), a 1M solution of 
SO2Cl2 in CH2Cl2 (0.13 mL, 0.128 mmol) in dry CH2Cl2 (4 mL) and biotin (39.1 mg, 0.160 
mmol), DBU (0.023 mL, 0.155 mmol) in dry CH2Cl2 (15 mL). The crude residue was purified by 
column chromatography on silica gel (gradient CH2Cl2/MeOH, 99:1, v/v; 97:3, v/v; 93:7, v/v). 
1H NMR (300 MHz, CDCl3) δ = 9.76 (s, 1H, NH-Thy), 7.35-7.37 (m, 11H, H-6 and Ar-H OBn), 
6.81 (br s, 1H, NH Bio), 6.31 (app t, J = 6.6 Hz, 1H, H-1’), 6.18 (br s, 1H, NH Bio), 5.13-4.99 
(m, 6H, OCH2O and 2 x OCH2Ph), 4.53-4.49 (m, 1H, H-3’), 4.38-4.35 (m, 1H, H-g Bio), 4.26-
4.12 (m, 3H, H-f Bio, H-5’ and H-5’’), 4.05-4.03 (m, 1H, H-4’), 3.16-3.12 (m, 1H, H-e Bio), 2.89 
(dd, J = 12.2, 7.2 Hz, 1H, H-h Bio), 2.79 (d, J = 12.2 Hz, 1H, H-h’ Bio), 2.58-2.52 (m, 1H, H-2’), 
2.40-2.27 (m, 3H, H-2’’ and H-a Bio), 1.80 (s, 3H, CH3), 1.76-1.69 (m, 4H, H-b and H-d Bio), 
1.52-1.43 (m, 2H, H-c Bio); 13C NMR (75 MHz, CDCl3) δ = 172.7 (OCO), 164.7 (C-4), 164.2 
(NHCONH), 150.7 (C-2), 135.5 (d, 3JC,P = 8.0 Hz, 1C of OCH2Ph), 134.5 (C-6), 128.8 (Ar-C), 
128.7 (Ar-C), 128.1 (Ar-C), 111.3 (C-5), 88.1 (OCH2O), 84.8 (C-1’), 83.1 (d, 3JC,P = 8.1 Hz, C-
4’), 81.3 (C-3’), 69.9-69.8 (2 x d, 2JC,P = 5.2 Hz, 2 x OCH2Ph), 67.0 (d, 2JC,P = 5.9 Hz, C-5’), 62.3 
(C-f Bio), 60.2 (C-g Bio), 55.6 (C-e Bio), 40.2 (C-h, h’ Bio), 38.6 (C-2’), 33.9 (C-a Bio), 28.2 (C-
c Bio), 28.0 (C-d Bio), 24.8 (C-b Bio), 12.5 (CH3-Thy); 31P NMR (121 MHz, CDCl3) δ = -0.4; 
HRMS for C35H43N4O11PS [M+Na]+ calcd.: 781.2279, found: 781.2288. 
 
4.6. 3’-O-(Biotinmethyloxyester)-thymidine monophosphate triethylammonium salt (7) 
 
10% Pd/C (Degussa, 15.0 mg, 50% w/w) was added to a degassed stirred solution of 4 (30.0 mg, 
0.039 mmol) and Et3N (0.011 mL, 0.079 mmol) in MeOH (10 mL), and the mixture was 
subjected to hydrogenation at atmospheric pressure using a balloon filled with H2 for 24 h. The 
catalyst was removed by filtration through a cellulose filter (0.45 μm) and the filtrate was 
concentrated under reduced pressure (bath temp 10-15 °C). The resulting crude residue was 
purified by RP-HPLC [TEAB (triethylammonium bicarbonate; 50 mmol) in H2O/MeCN, 98:2; 
and TEAB (50 mmol) in H2O/MeCN, 50:50]. The collected eluate was freeze-dried repeatedly 
until constant mass to obtain the triethylammonium salt of 7 (22.2 mg, 72%) as a white solid. 1H 
NMR (500 MHz, D2O) δ = 7.80 (s, 1H, H-6), 6.28 (app t, J = 7.3 Hz, 1H, H-1’), 5.46-5.32 (m, 
2H, OCH2O), 4.63-4.62 (m, 1H, H-3’), 4.56-4.54 (m, 1H, H-g Bio), 4.38-4.36 (m, 1H, H-f Bio), 
4.25 (br s, 1H, H-4’), 3.94-3.88 (m, 2H, H-5’ and H-5’’), 3.29-3.25 (m, 1H, H-e Bio), 2.92 (dd, J 
= 13.0, 5.0 Hz, 1H, H-h), 2.70 (d, 1H, J = 13.0 Hz, H-h’ Bio), 2.45 (t, 2H, J = 7.2 Hz, H-a Bio), 
2.42-2.40 (m, 1H, H-2’ and H-2’’), 1.88 (s, 3H, CH3), 1.73-1.52 (m, 4H, H-b and H-d Bio), 1.43-
1.36 (m, 2H, H-c Bio) ; 13C NMR (125 MHz, D2O) δ = 175.5 (OCO), 168.3 (C-4), 164.8 
(NHCONH), 152.9 (C-2), 137.0 (C-6), 111.4 (C-5), 88.1 (OCH2O), 84.3 (C-1’), 83.8 (d, 3JC,P = 
9.2 Hz, C-4’), 80.7 (C-3’), 63.3 (d, 2JC,P = 3.9  Hz , C-5’), 61.5 (C-f Bio), 59.7 (C-g Bio), 54.8 (C-
e Bio), 39.2 (C-h, h’ Bio), 36.6 (C-2’), 33.1 (C-a Bio), 27.4 (C-c), 27.1 (C-d Bio), 23.4 (C-b Bio), 
11.5 (CH3-Thy); 31P NMR (202 MHz, D2O) δ = 3.4; HRMS for C21H31N4O11PS [M-H]- calcd.: 
577.1375, found: 577.1375. 
 
4.7. 5’-O-(Dibenzylphosphate)-3’-O-(biotincarboxamide)-thymidine (9) 
 
DCC (127.4 mg, 0.618 mmol) was added to a stirred solution of 8 (200.0 mg, 0.386 mmol), biotin 
(108.6 mg, 0.444 mmol), and DMAP (2.0 mg, 0.016 mmol) in a mixture of dry DMF (2.0 mL) 
and dry CH2Cl2 (10 mL) at 0 °C. The reaction mixture was allowed to warm slowly to room 
temperature and stirred for 24 h. All the volatiles were removed under reduced pressure and the 
resulting residue was purified by column chromatography on silica gel (gradient CH2Cl2/MeOH, 
99:2, v/v; 97:4, v/v; 94:7, v/v) to give 9 (201.0 mg, 70%) as a colourless foam. 1H NMR (300 
MHz, CDCl3 + CD3OD) δ = 7.41 (d, J = 1.0 Hz, 1H, H-6), 7.39-7.34 (m, 10H, Ar-H OBn), 6.27 
(dd, J = 8.9, 5.6 Hz, 1H, H-1’), 5.12-5.00 (m, 4H, 2 x OCH2Ph), 4.55-4.48 (m, 2H, H-3’ and H-g 
Bio), 4.33-4.29 (m, 2H, H-4’ and H-f Bio,), 4.23-4.22 (m, 2H, H-5’ and H-5’’), 3.21-3.15 (m, 1H, 
H-e Bio), 2.91 (dd, J = 12.8, 4.9 Hz, 1H, H-h Bio), 2.73 (d, J = 12.8 Hz, 1H, H-h’ Bio), 2.54-2.48 
(m, 1H, H-2’), 2.14 (t, J = 6.7 Hz, 3H, H-a Bio), 1.94-1.84 (m, 1H, H-2’’), 1.81 (d, J = 0.9 Hz, 
3H, CH3), 1.75-1.61 (m, 4H, H-b and H-d Bio), 1.51-1.43 (m, 2H, H-c Bio) ; 13C NMR (75 MHz, 
CDCl3 + CD3OD) δ = 172.8 (ONHCO), 165.1 (C-4), 164.9 (NHCONH), 151.3 (C-2), 136.0 (C-
6), 135.6 (d, 3JC,P = 5.7 Hz, 1C of OCH2Ph), 129.4 (Ar-C), 129.1 (Ar-C), 128.5 (Ar-C), 111.8 (C-
5), 85.4 (C-3’), 85.3 (C-1’), 81.6 (d, 3JC,P = 8.3 Hz, C-4’), 70.5-70.4 (d, 2JC,P = 5.6 Hz, 2 x 
OCH2Ph), 68.1 (d, 2JC,P = 5.8 Hz , C-5’), 62.4 (C-f Bio), 60.6 (C-g Bio), 55.9 (C-e Bio), 40.6 (C-
h, h’ Bio), 36.4 (C-2’), 32.8 (C-a Bio), 28.7 (C-c Bio), 28.5 (C-d Bio), 25.5 (C-b Bio), 12.4 (CH3-
Thy); 31P NMR (121 MHz, CDCl3) δ = -1.0; HRMS for C34H42N5O10PS [M+Na]+ calcd.: 
766.2282, found: 766.2302. 
 
4.8. 3’-O-(Biotincarboxamide)-thymidine monophosphate triethylammonium salt (10) 
 
Following a similar procedure as the one used for the synthesis of 7, the triethylammonium salt of 
compound 10 was obtained as a white solid (169.0 mg, 82%), starting from 9 (200.0 mg, 0.269 
mmol), Et3N (0.075 mL, 0.538 mmol) and 10% Pd/C Degussa (100 mg, 50% w/w) in MeOH (20 
mL). 1H NMR (500 MHz, D2O) δ = 7.90 (s, 1H, H-6), 6.40 (dd, J = 9.1, 5.7 Hz, 1H, H-1’), 4.73-
4.72 (m, 1H, H-3’), 4.56-4.54 (m, 1H, H-g Bio), 4.38-4.35 (m, 1H, H-f Bio), 4.32 (br s, 1H, H-
4’), 3.92-3.91 (m, 2H, H-5’ and H-5’’), 3.32-3.28 (m, 1H, H-e Bio), 2.93 (dd, J = 13.0, 4.9 Hz, 
1H, H-h), 2.69 (d, 1H, J = 13.0 Hz, H-h’ Bio), 2.48-2.44 (m, 1H, H-2’),  2.40-2.34 (m, 1H, H-
2’’), 2.15 (t, 2H, J = 7.0 Hz, H-a Bio), 1.89 (s, 3H, CH3), 1.72-1.67 (m, 1H, H-b Bio), 1.65-1.60 
(m, 2H, H-d Bio), 1.59-1.51 (m, 1H, H-b’ Bio), 1.40-1.34 (m, 2H, H-c Bio) ; 13C NMR (125 
MHz, D2O) δ = 172.8 (ONHCO), 166.9 (C-4), 164.8 (NHCONH), 151.8 (C-2), 137.3 (C-6), 
111.4 (C-5), 84.9 (C-3’), 84.3 (C-1’), 82.1 (d, 3JC,P = 8.9 Hz, C-4’), 63.6 (d, 2JC,P = 3.9  Hz, C-5’), 
61.4 (C-f Bio), 59.7 (C-g Bio), 54.7 (C-e Bio), 39.2 (C-h, h’ Bio), 34.8 (C-2’), 31.8 (C-a Bio), 
27.3 (C-c Bio), 27.0 (C-d Bio), 24.5 (C-b Bio), 11.3 (CH3-Thy); 31P NMR (202 MHz, D2O) δ = 
3.4; HRMS for C20H30N5O10PS [M-H]- calcd.: 562.1378, found: 562.1382. 
 
4.9. 5’-O-(Dibenzylphosphate)-3’-O-(biotinmethyloxycarboxamide)-thymidine (12) 
 
Following a similar procedure as the one used for the synthesis of 9, compound 12 was obtained 
as a colorless foam (214.0 mg, 76%), starting from 11 (200 mg, 0.365 mmol), biotin (102.6 mg, 
0.420 mmol), DCC (120.6 mg, 0.584 mmol) and DMAP (1.8 mg, 0.0146 mmol) in a mixture of 
dry DMF (2.0 ml) and dry CH2Cl2 (10 ml). 1H NMR (300 MHz, DMSO-d6) δ = 11.34 (br s, 1H, 
NH), 11.00 (br s, 1H, NH), 7.50 (s, 1H, H-6), 7.35-7.35 (m, 10H, Ar-H OBn), 6.41 (br s, 1H, NH 
Bio), 6.35 (br s, 1H, NH Bio), 6.15 (dd, J = 8.2, 5.9 Hz, 1H, H-1’), 5.06 (d, J = 8.0 Hz, 4H, 2 x 
OCH2Ph), 4.87-4.81 (m, 2H, OCH2O), 4.51-4.50 (m, 1H, H-3’), 4.33-4.29 (m, 3H, H-g Bio, H-f 
Bio and H-4’), 4.19-4.10 (m, 2H, H-5’ and H-5’’), 3.10-3.04 (m, 1H, H-e Bio), 2.81 (dd, J = 12.6, 
5.2 Hz, 1H, H-h Bio), 2.57 (d, J = 12.6 Hz, 1H, H-h’ Bio), 2.35-2.28 (m, 1H, H-2’), 2.17-2.08 (m, 
1H, H-2’’), 2.00 (t, J = 7.0 Hz, 3H, H-a Bio), 1.69 (s, 3H, CH3), 1.63-1.42 (m, 4H, H-b and H-d 
Bio), 1.36-1.27 (m, 2H, H-c Bio) ; 13C NMR (75 MHz, DMSO-d6) δ = 169.6 (ONHCO), 163.6 
(C-4), 162.7 (NHCONH), 150.4 (C-2), 135.9 (d, 3JC,P = 6.9 Hz, 1C of OCH2Ph), 135.6 (C-6), 
128.5 (Ar-C), 128.4 (Ar-C), 127.8 (Ar-C), 109.9 (C-5), 97.0 (OCH2O), 84.0 (C-1’), 82.3 (d, 3JC,P 
= 7.6 Hz, C-4’), 77.1 (C-3’), 68.7 (d, 2JC,P = 5.4 Hz, 2 x OCH2Ph), 67.1 (d, 2JC,P = 5.0 Hz , C-5’), 
61.0 (C-f Bio), 59.2 (C-g Bio), 55.3 (C-e Bio), 39.5 (C-h, h’ Bio), 36.2 (C-2’), 32.0 (C-a Bio), 
28.1 (C-c Bio), 28.0 (C-d Bio), 24.9 (C-b Bio), 12.0 (CH3-Thy); 31P NMR (121 MHz, CDCl3) δ = 
-0.9; HRMS for C35H44N5O11PS [M+Na]+ calcd.: 796.2388, found: 796.2403. 
 
4.10. 3’-O-(Biotinmethyloxycarboxamide)-thymidine monophosphate triethylammonium 
salt (13) 
 
Following a similar procedure as the one used for the synthesis of 7, the triethylammonium salt of 
compound 13 was obtained as a white solid (170.6 mg, 79%), starting from 12 (210 mg, 0.271 
mmol), Et3N (0.075 mL, 0.543 mmol) and 10% Pd/C Degussa (105 mg, 50% w/w) in MeOH (20 
mL). 1H NMR (500 MHz, D2O) δ = 7.85 (d, J = 1.1 Hz, 1H, H-6), 6.31 (app t, J = 7.3 Hz, 1H, H-
1’), 4.98 (s, 2H, OCH2O), 4.71-4.70 (m, 1H, H-3’), 4.57-4.54 (m, 1H, H-g Bio), 4.39-4.37 (m, 
1H, H-f Bio), 4.28-4.27 (m, 1H, H-4’), 3.97-3.90 (m, 2H, H-5’ and H-5’’), 3.31-3.27 (m, 1H, H-e 
Bio), 2.94 (dd, J = 13.0, 5.0 Hz, 1H, H-h), 2.71 (d, 1H, J = 13.0 Hz, H-h’ Bio), 2.42-2.39 (m, 1H, 
H-2’ and H-2’’), 2.20 (t, 2H, J = 7.0 Hz, H-a Bio), 1.89 (d, J = 1.1 Hz, 3H, CH3), 1.70-1.54 (m, 
1H, H-b and H-d Bio), 1.39-1.37 (m, 2H, H-c Bio) ; 13C NMR (125 MHz, D2O) δ = 172.9 
(ONHCO), 166.2 (C-4), 164.8 (NHCONH), 151.3 (C-2), 137.2 (C-6), 111.4 (C-5), 96.8 
(OCH2O), 84.3 (C-1’), 83.8 (d, 3JC,P = 8.7 Hz, C-4’), 78.4 (C-3’), 63.4 (d, 2JC,P = 3.7 Hz , C-5’), 
61.5 (C-f Bio), 59.7 (C-g Bio), 54.8 (C-e Bio), 39.2 (C-h, h’ Bio), 36.1 (C-2’), 31.5 (C-a Bio), 
27.2 (C-c Bio), 27.1 (C-d Bio), 24.2 (C-b Bio), 11.2 (CH3-Thy); 31P NMR (202 MHz, D2O) δ = 
2.8; HRMS for C21H32N5O11PS [M-H]- calcd.: 592.1484, found: 592.1480. 
 
4.11. 5’-O-(Dibenzylphosphate)-3’-O-(biotinester)-thymidine (14) 
 
Following a similar procedure as the one used for the synthesis of 9, compound 14 was obtained 
(370.0 mg, 74%) as a colorless foam, starting from 5 (345 mg, 0.686 mmol), biotin (201.0 mg, 
0.823 mmol), DCC (198.0 mg, 0.960 mmol) and DMAP (8.0 mg, 0.068 mmol) in a mixture of 
dry DMF (3 ml) and dry CH2Cl2 (15 ml). 1H NMR (300 MHz, CDCl3) δ = 10.95 (br s, 1H, NH 
Thy), 7.40 (s, 1H, H-6), 7.34-7.33 (m, 10H, Ar-H OCH2Ph), 6.76 (br s, 1H, NH Bio), 6.50 (br s, 
1H, NH Bio), 6.26 (app t, J = 6.7 Hz, 1H, H-1’), 5.13-5.00 (m, 5H, H-3’ and OCH2Ph ), 4.51-
4.50 (m, 1H, H-g Bio), 4.30-4.22 (m, 1H, H-f Bio, H-5’ and H-5’’), 4.11 (br s, 1H, H-4’), 3.17-
3.15 (m, 1H, H-e Bio), 2.91-2.88 (m, 1H, H-h Bio), 2.78-2.74 (m, 1H, H-h’ Bio), 2.35-2.25 (m, 
3H, H-a Bio and H-2’), 1.97-1.94 (m, 1H, H-2’’), 1.81 (s, 3H, CH3), 1.69-1.60 (m, 4H, H-b and 
H-d Bio), 1.46-1.44 (m, 2H, H-c Bio) ; 13C NMR (75 MHz, CDCl3) δ = 172.7 (OCO), 164.3 (C-
4), 164.2 (NHCONH), 150.5 (C-2), 135.1 (d, 3JC,P = 6.1 Hz, 1C of OCH2Ph), 134.7 (C-6), 128.5 
(Ar-C), 128.3 (Ar-C), 127.7 (Ar-C), 111.2 (C-5), 84.1 (C-1’), 82.4 (d, 3JC,P = 8.1 Hz, C-4’), 74.1 
(C-3’), 69.4 (app t, 2JC,P = 4.7 Hz, 2 x OCH2Ph), 66.8 (d, 2JC,P = 4.7 Hz , C-5’), 61.7 (C-f Bio), 
60.0 (C-g Bio), 55.2 (C-e Bio), 40.2 (C-h, h’ Bio), 36.8 (C-2’), 33.4 (C-a Bio), 28.0 (C-c Bio), 
27.8 (C-d Bio), 24.3 (C-b Bio), 12.0 (CH3-Thy); 31P NMR (121 MHz, CDCl3) δ = -0.7; HRMS 
for C34H41N4O10PS [M+H]+ calcd.: 729.2353, found: 729.2354. 
 
4.12. 3’-O-(Biotinester)-thymidine monophosphate triethylammonium salt (15) 
 
Following a similar procedure as the one used for the synthesis of 7, the triethylammonium salt of 
compound 15 was obtained as a white solid (335.0 mg, 88%), starting from 14 (370.0 mg, 0.686 
mmol), Et3N (0.141 mL, 1.015 mmol) and 10% Pd/C (Degussa, 185.0 mg, 50% w/w) in MeOH 
(30 ml). 1H NMR (600 MHz, DMSO-d6) δ = 11.34 (br s, 1H, NH Thy), 7.91 (s, 1H, H-6), 6.51 
(br s, 1H, NH Bio), 6.40 (br s, 1H, NH Bio), 6.23 (dd, J = 9.0, 5.8 Hz, 1H, H-1’), 5.28-5.27 (m, 
1H, H-3’), 4.32-4.30 (m, 1H, H-g Bio), 4.15-4.12 (m, 1H, H-f Bio), 4.07 (br s, 1H, H-4’), 3.90-
3.83 (m, 2H, H-5’ and H-5’’), 3.13-3.10 (m, 1H, H-e Bio), 2.83-2.82 (m, 1H, H-h Bio merged 
with triethylamine), 2.58 (d, 1H, J = 12.4 Hz, H-h’ Bio), 2.36 (t, 2H, J = 7.1 Hz, H-a Bio), 2.33-
2.29 (m, 1H, H-2’), 2.21-2.17 (m, 1H, H-2’’), 1.81 (s, 3H, CH3), 1.66-1.62 (m, 1H, H-b Bio), 
1.61-1.55 (m, 2H, H-d Bio), 1.51-1.44 (m, 1H, H-b’ Bio), 1.39-1.32 (m, 2H, H-c Bio); 13C NMR 
(150 MHz, DMSO-d6) δ = 172.6 (OCO), 163.9 (C-4), 162.9 (NHCONH), 150.7 (C-2), 136.2 (C-
6), 110.3 (C-5), 83.7 (C-1’), 83.5 (d, 3JC,P = 7.4 Hz, C-4’), 75.5 (C-3’), 64.2 (d, 2JC,P = 6.0 Hz , C-
5’), 61.1 (C-f Bio), 59.3 (C-g Bio), 55.4 (C-e Bio), 39.6 (C-h,h’ Bio merged with DMSO), 36.5 
(C-2’), 33.4 (C-a Bio), 28.0 (C-c and C-d Bio), 24.5 (C-b Bio), 12.2 (CH3-Thy); 31P NMR (202 
MHz, DMSO-d6) δ = -0.1; HRMS for C20H29N4O10PS [M-H]- calcd.: 547.1269, found: 547.1279. 
 
4.13. N-Boc kanamycin A (17) 
 
To a stirred solution of kanamycin A 16 (1.8 g, 3.71 mmol) in a mixture of DMF:H2O (4:1, 48 
mL), was added di-tert-butyldicarbonate (5.12 mL, 22.29 mmol) and the solution was heated at 
60 °C for 5h and then cooled to room temperature. After removal of all the volatiles, the resulting 
residue was washed with hexane (2 x 100 ml) and then with water (3 x 100 mL), and finally dried 
in vacuo to afford 17 (2.99 g, 91%) as a white solid. Rf  = 0.4 (10% MeOH in DCM). 1H NMR 
(300 MHz, DMSO-d6) δ = 6.89 (br s, 1H), 6.58 (br s, 1H), 6.50 (d, J = 8.6 Hz, 1H), 6.34 (br s, 
1H), 5.35 (d, J = 3.8 Hz, 1H), 5.26 (s, 1H), 4.89 (m, 4H), 4.68 (d, J = 6.2 Hz, 1H), 4.19 (t, J = 5.4 
Hz, 1H), 3.82 (m, 1H), 3.61-3.35 (m, 9H), 3.30-3.17 (m, 6H), 3.07 (m, 1H), 1.80 (m, 1H), 1.40-
1.35 (m, 37H); 13C NMR (75 MHz, DMSO-d6) δ = 156.3, 156.1, 155.3, 154.9, 101.1, 97.8, 84.0, 
80.3, 77.8, 77.7, 77.2, 75.0, 72.9, 72.7, 72.1, 70.5, 70.3, 70.1, 67.4, 60.3, 55.9, 50.0, 49.1, 41.4, 
34.7, 28.3, 28.2, 28.1; HRMS [ESI+] for C38H68N4O19 [M+H]+calcd.: 885.4550, found: 885.4552. 
 
4.14. O-TIBS-N-Boc kanamycin A (18) 
 
To a stirred solution of 17 (2.48 g, 2.81 mmol) in dry pyridine (50 mL) was added 2,4,6-
triisopropylbenzenesulfonyl chloride (5.96 g, 19.67 mmol) and the solution was stirred at 25 °C 
for 16h. The reaction mixture was neutralized by adding 1N HCl and diluted with water. The 
aqueous layer was extracted with ethyl acetate (3 x 400 mL). The collected organic fractions were 
washed with brine, dried over Na2SO4 and concentrated in vacuo. The crude residue was purified 
by column chromatography over silica gel (3% MeOH in DCM) to afford 18 (1.91 g, 59%) as a 
white solid. Rf  = 0.48 (10% MeOH in DCM). 1H NMR (300 MHz, CD3OD) δ = 7.28 (s, 1H), 
6.58 (br s, 1H), 5.35 (d, J = 3.8 Hz, 1H), 5.04 (m, 2H), 4.38 (m, 2H), 4.14 (m, 3H), 3.71-3.31 (m, 
12H), 3.18 (t, J = 9.4 Hz, 1H), 2.95 (m, 1H), 2.02 (m, 1H), 1.45-1.41 (m, 37H), 1.28-1.25 (m, 
18H); 13C NMR (75 MHz, CD3OD) δ = 159.4, 159.2, 157.9, 157.7, 155.3, 152.3, 130.7, 124.9, 
102.8, 99.8, 85.8, 80.9, 80.6, 80.4, 80.2, 76.8, 74.5, 73.9, 72.3, 71.9, 71.7, 71.6, 69.2, 57.4, 52.2, 
50.9, 41.9, 36.0, 35.5, 30.8, 28.9, 28.8, 28.7, 25.2, 25.1, 23.9; HRMS [ESI+] for C53H90N4O21S 
[M+H]+calcd.: 1151.5890, found: 1151.5895. 
 
4.15. N-Boc kanamycin A cysteamine (19) 
 
To a stirred solution of 18 (0.9 g, 0.782 mmol) in DMF (30 mL) was added 2-
mercaptoethylamine hydrochloride (0.67 g, 5.86 mmol) followed by cesium carbonate (2.55 g, 
7.82 mmol) and the solution was stirred at 25 °C for 16h. DMF was partly removed in vacuo and 
then partitioned between water (150 ml) and ethyl acetate (300 ml). The aqueous layer was 
extracted with ethyl acetate (2 x 150 mL). The collected organic fractions were washed with 
brine, dried over Na2SO4 and concentrated in vacuo. The crude residue was purified by column 
chromatography over silica gel (5% MeOH in DCM) to afford 19 (0.45 g, 61%) as an off-white 
solid. Rf = 0.38 (10% MeOH in DCM). 1H NMR (300 MHz, CD3OD) δ = 5.13 (d, J = 3.5 Hz, 
1H), 5.08 (d, J = 3.3 Hz, 1H), 4.17 (t, J = 6.7 Hz, 1H), 3.72-3.52 (m, 6H), 3.47-3.38 (m, 7H), 3.21 
(m, 3H), 3.05 (m, 1H), 2.90-2.81 (m, 3H), 2.68 (dd, J = 14.5, 6.8 Hz, 1H), 2.12 (m, 1H), 1.46-
1.43 (m, 37H); 13C NMR (75 MHz, CD3OD) δ = 159.4, 159.2, 158.1, 157.7, 102.6, 100.6, 85.2, 
83.2, 80.6, 80.4, 80.2, 71.2, 74.5, 74.0, 73.8, 72.4, 72.1, 72.0, 71.8, 57.0, 52.0, 50.8, 41.8, 40.0, 
35.9, 34.7, 31.4, 30.4, 28.9, 28.8, 28.8, 28.7, 24.2; HRMS [ESI+] for C40H73N5O18S 
[M+H]+calcd.: 944.4744, found: 944.4733. 
 
4.16. 5’-O-(Dibenzylphosphate)-3’-O-(N-Boc-kanamycin A cysteamine carbamate)-
thymidine (21) 
 
To a stirred solution of compound 19 (353 mg, 0.374 mmol) in 1,4-dioxane/water (3:1, 8 mL) 
was added 20 (250 mg, 0.374 mmol) followed by triethylamine (0.052 mL, 0.374 mmol) at 0 °C 
and then the solution was stirred at room temperature for 16 h. After completion of the reaction, 
the mixture was evaporated to dryness in vacuo and the residue was purified by column 
chromatography (4% MeOH in DCM) to obtain compound 21 (495 mg, 90%) as a white solid. Rf  
= 0.45 (10% MeOH in DCM). 1H NMR (500 MHz, CD3OD) δ = 7.47 (s, 1H), 7.36 (s, 10H), 6.25 
(dd, J = 8.6, 5.8 Hz, 1H), 5.14-5.07 (m, 6H), 5.05 (br s, 1H), 4.29 (m, 2H), 4.20 (m, 2H), 3.71-
3.60 (m, 4H), 3.55-3.48 (m, 4H), 3.42-3.32 (m, 6H), 3.19 (t, J = 9.3 Hz, 1H), 3.02 (dd, J = 13.9, 
2.1 Hz, 1H), 2.75-2.62 (m, 3H), 2.33 (dd, J = 14.2, 5.5 Hz, 1H), 2.07 (m, 1H), 1.76 (s, 3H), 1.44-
1.42 (m, 37H); 13C NMR (125 MHz, CD3OD) δ = 166.18, 159.5, 159.2, 158.0, 157.7, 152.3, 
137.2, 137.1 (d, 3JC,P = 2.3 Hz), 137.0 (d, 3JC,P = 2.3 Hz), 130.0, 129.8, 129.3, 112.2, 102.7, 
100.2, 86.3, 84.4 (d, 3JC,P = 7.8 Hz), 80.6, 80.5, 80.4, 80.2, 77.2, 76.0, 74.7, 74.1, 73.7, 72.5, 72.4, 
72.3, 71.8, 71.2 (2 x d, 2JC,P = 5.8 Hz), 68.8 (d, 2JC,P = 6.1 Hz), 57.2, 50.9, 41.7, 38.2, 35.0, 33.9, 
28.9, 28.9, 28.9, 28.8, 28.8, 12.6; 31P NMR (202 MHz, CD3OD) δ = -0.03; HRMS [ESI+] for 
C65H98N7O27PS [M+Na]+calcd.: 1494.5861, found: 1494.5873. 
 
4.17. 3’-O-(kanamycin A cysteamine carbamate)-TMP (22) 
 
To a stirred solution of 21 (200 mg, 0.136 mmol, 1 eq.) in EtOH/H2O (8:2, 15 mL), was added 
20% Pd(OH)2/C (160 mg, 0.8 eq w/w) and evacuation was then carried out with hydrogen 
atmosphere replacements (3x). The reaction mixture was stirred at room temperature for 24h 
under an atmospheric pressure of hydrogen. After completion of the reaction, the catalyst was 
removed by filtration through a cellulose filter (0.45 μm) and the filtrate was concentrated under 
reduced pressure to obtain crude 3’-O-(N-Boc-kanamycin A cysteamine carbamate)-TMP (~175 
mg, quant.). The so obtained residue was treated without further purification with 90% aq. TFA 
(5 mL) at 0 °C and then the solution was stirred at room temperature for 5h. After completion of 
the reaction, the mixture was evaporated to dryness in vacuo. The residue was coevaporated three 
times with toluene to remove residual TFA and to give crude 3’-O-(kanamycin A cysteamine 
carbamate)-TMP. The crude residue was purified by preparative RP-HPLC (0.1% TFA in 98% 
H2O + 2% ACN and 0.1% TFA in 98% ACN + 2% H2O). The collected eluates were freeze-
dried repeatedly until constant mass to afford compound 21 (86 mg, 71% over two steps) as 
trifluoroacetic salt. 31P NMR (202 MHz, D2O) δ = -0.02; HRMS [ESI-] for C31H54N7O19PS [M-
H]- calcd.: 890.2860, found: 890.2852. 
 
4.18. 5’-O-(Dibenzylphosphate)-3’-O-(kanamycin A carbamate)-thymidine (23) 
 
Compound 23 was obtained according to the procedure for the preparation of compound 21 
starting from kanamycin A 16 (100 mg, 0.206 mmol), compound 20 (138 mg, 0.206 mmol) and 
triethylamine (29 μL, 0.206 mmol). The crude residue was purified by column chromatography 
(IPA:H2O:Et3N 10:2:1) to give 23 as a white solid (171 mg, 82%). Rf  = 0.45 (IPA:H2O:Et3N 
6:2:2). 1H NMR (300 MHz, D2O) δ = 7.16 (s, 1H), 7.09 (s, 10H), 6.1 (app t, J = 6.0 Hz, 1H), 5.21 
(d, J = 5.5 Hz, 1H), 5.01 (m, 2H), 4.84 (m, 4H), 4.19-3.89 (m, 4H), 3.81-3.08 (m, 14H), 2.99 (t, J 
= 10.4 Hz, 1H), 2.82 (t, J = 11.3 Hz, 1H), 2.31 (m, 1H), 2.04-1.80 (m, 2H), 1.52 (s, 3H), 1.33-
1.19 (m, 1H); 13C NMR (75 MHz, D2O) δ = 165.3, 156.8, 151.0, 135.7, 134.8 (d, 3JC,P = 5.3 Hz), 
128.5, 128.3, 127.7, 127.6, 127.1, 110.8, 99.9, 99.7, 86.8, 86.1, 84.6, 82.2, 74.2, 73.7, 72.4, 72.0, 
71.5, 71.2, 70.6, 70.4, 69.6, 67.8, 67.0, 59.8, 54.2, 50.0, 48.9, 41.0, 36.2, 33.5, 11.5; 31P NMR 
(121 MHz, D2O) δ = -0.89; HRMS [ESI+] for C43H61N6O20P [M+H]+calcd.: 1013.3751, found: 
1013.3745. 
 
4.19. 3’-O-(kanamycin A carbamate)-TMP (24) 
 
Compound 24 was obtained as a white solid (86.7 mg, 88%) starting from compound 23 (120 mg, 
0.118 mmol) following the same hydrogenation procedure described for compound 22, using 
20% Pd(OH)2/C (24 mg, 0.2 eq w/w). 31P NMR (202 MHz, D2O) δ = -0.02; HRMS [ESI-] for 
C29H49N6O20P [M-H]- calcd.: 831.2666, found: 831.2666. 
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